Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
238 hedge funds and large institutions have $6.08B invested in Acceleron Pharma in 2020 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 98 increasing their positions, 71 reducing their positions, and 49 closing their positions.
47% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $15.3M
38% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 71
32% more capital invested
Capital invested by funds: $4.6B → $6.08B (+$1.49B)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 49
2% less funds holding
Funds holding: 242 → 238 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$178M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$75.3M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$73.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$49.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$183M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$44.2M |
| 3 |
Millennium Management
New York
|
-$18.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.1M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$15.7M |
XLRN Hedge Fund Activity: Q3 2020 in Review
238 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2020, worth a combined $6.08B — up 32% from $4.6B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of XLRN and 45 opened new positions — a net loss of 4 holders — while 71 trimmed existing stakes and 98 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $178M. The largest seller was Fidelity Investments, cutting an estimated $183M.
- 238 institutional investors held Acceleron Pharma (XLRN) as of Q3 2020, down from 242 in Q2 2020.
- Funds reported $6.08B of Acceleron Pharma stock for Q3 2020, up 32% quarter-over-quarter.
- 45 funds opened new Acceleron Pharma positions in Q3 2020 and 49 closed out, a net change of -4 holders.
- The largest Acceleron Pharma buyer in Q3 2020 was Janus Henderson Group, an estimated $178M added.
- The largest Acceleron Pharma seller in Q3 2020 was Fidelity Investments, an estimated $183M sold.
Based on aggregated 13F filings for Q3 2020.